

ADVISORY COMMITTEE
of the Connecticut Bioscience Innovation Fund
Minutes – Regular Meeting
Wednesday, August 17, 2022

A regular meeting of the **Connecticut Bioscience Innovation Fund** (“the Bioscience Fund” or “CBIF”) **Advisory Committee** (the “Committee”) was held electronically through Microsoft Teams on August 17, 2022.

1. Call to Order:

Noting the presence of a quorum, Matt McCooe, Chairperson of the Committee, called the meeting to order at 10:02 a.m.

Committee Members Present: Peter Farina, Ph.D.; William LaRoche, Ph.D.; Charles Lee, Ph.D.; Chris McLeod; Matt McCooe; Alan Mendelson; Kevin Rakin; and Jonathan Soderstrom, Ph.D.

Absent: David Lehman; Anthony Muyombwe, Ph.D.; David Scheer; and Sandra Weller, Ph. D.

Staff Attending: Stanley Chen, Cyndi Greene, Ph.D.; Stepheni Harpin; Malik Lewis; Peter Longo; Jordan Lue; Matthew McCooe; Elizabeth Skrabi; and Daniel Wagner.

2. Approval of Minutes:

Mr. McCooe asked the Committee members to consider the minutes from the July 20, 2022, regular meeting.

Upon a motion made by Mr. Rakin and seconded by Dr. Farina, the Advisory Committee members voted unanimously in favor of adopting the minutes from the July 20, 2022, regular meeting, as presented.

At 10:09 a.m. Dr. Feuerstein joined the meeting

3. Other Business:

“BioRez, Inc. Update”

Mr. Wagner presented a brief update on BioRez, Inc.

“Celloryx/Aurealis Pharma AG – Switzerland”

Mr. Wagner and Dr. Green discussed the history of CI’s investment in Celloryx/Aurealis Pharma AG and the current strategic plan of the company.

A discussion ensued.

Upon a motion made by Mr. McLeod and seconded by Dr. Lee, the Advisory Committee members voted unanimously in favor of the execution by Connecticut Innovations Inc. (“CI”) on items for action, as presented, for Celloryx/Aurealis Pharma AG.

“Oova, Inc. – Stamford, CT”

Dr. Green discussed Oova, Inc. and outlined the proposed revisions to certain terms from those presented in the July 20, 2022, Connecticut Bioscience Innovation Fund Advisory Committee meeting.

A discussion ensued.

Upon a motion made by Mr. Rakin and seconded by Dr. Feuerstein, the Advisory Committee members voted unanimously in favor of the proposed revisions, as presented, for Oova, Inc.

6. Date of Next Meeting:

September 14, 2022, at 10:00 a.m.

7. Adjournment:

Upon a motion made by Mr. McLeod, seconded by Mr. Rakin, the Advisory Committee members voted unanimously in favor of adjourning the meeting at 10:30 a.m.

Respectfully Submitted,



[Matt McCooe \(Sep 16, 2022 15:20 EDT\)](#)

Matthew McCooe
Chairperson






08-17-2022 - CBIF Minutes

Final Audit Report

2022-09-16

| | |
|-----------------|---|
| Created: | 2022-09-14 |
| By: | Elizabeth Skrabl (elizabeth.skrabl@ctinnovations.com) |
| Status: | Signed |
| Transaction ID: | CBJCHBCAABAAI6Pjbr-UklnAeGuyGbh0W33sENqPYOqy |

"08-17-2022 - CBIF Minutes" History

-  Document created by Elizabeth Skrabl (elizabeth.skrabl@ctinnovations.com)
2022-09-14 - 6:49:05 PM GMT
-  Document emailed to Matt McCooe (matt.mccooe@ctinnovations.com) for signature
2022-09-14 - 6:49:23 PM GMT
-  Email viewed by Matt McCooe (matt.mccooe@ctinnovations.com)
2022-09-16 - 7:19:55 PM GMT
-  Document e-signed by Matt McCooe (matt.mccooe@ctinnovations.com)
Signature Date: 2022-09-16 - 7:20:04 PM GMT - Time Source: server
-  Agreement completed.
2022-09-16 - 7:20:04 PM GMT